Role of fibulin-3 in lung cancer: In vivo and in vitro analyses

Xu,Shun; Yang,Yong; Sun,Yan-Bin; Wang,Hao-You; Sun,Chang-Bo; Zhang,Xin

doi:10.3892/or.2013.2799

Role of fibulin-3 in lung cancer: In vivo and in vitro analyses

Authors:
- Shun Xu
- Yong Yang
- Yan-Bin Sun
- Hao-You Wang
- Chang-Bo Sun
- Xin Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, P.R. China, Sujiatun Center Hospital, Shenyang, Liaoning, P.R. China
Published online on: October 18, 2013 https://doi.org/10.3892/or.2013.2799
Pages: 79-86

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer was the most commonly diagnosed cancer in 2008 worldwide. The level of fibulin-3 expression was found to be decreased in many cancer types due to aberrant promoter methylation and is correlated with poor survival of patients. However, the role of fibulin-3 and which form of fibulin-3 is expressed in lung cancer cells remain unclear. Therefore, pathologic and functional studies were carried out to determine the role of fibulin-3 in suppressing lung cancer both in vivo and in vitro. In the present study, we found that the levels of fibulin-3 mRNA and protein were lower in cancer tissues than in normal tissues. Downregulation of fibulin-3 mRNA in tumor tissues was associated with an increase in fibulin-3 promoter methylation. Circulating fibulin-3 was significantly associated with tumor progression, survival rate of lung cancer patients, and the number of circulating tumor cells (CTCs). To examine the effects of exogenous expression of fibulin-3 in vitro, lung cancer A549 cells were transfected with the pEGFP-C1-fibulin-3 expression vector. Relative to the untreated cells, fibulin-3-expressing cells exhibited lower proliferation and mobility as determined by MTT and Transwell assays, respectively. To conclude, our results suggest that fibulin-3 negatively modulates the invasiveness of lung cancer cells via regulation of p38-MAPK and MMP-2/9.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Lam WK, White NW and Chan-Yeung MM: Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis. 8:1045–1057. 2004.PubMed/NCBI
3	Kobayashi N, Kostka G, Garbe JH, et al: A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J Biol Chem. 282:11805–11816. 2007. View Article : Google Scholar
4	Timpl R, Sasaki T, Kostka G and Ghu ML: Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 4:479–489. 2003. View Article : Google Scholar : PubMed/NCBI
5	Pupa SM, Giuffré S, Castiglioni F, et al: Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 67:4271–4277. 2007. View Article : Google Scholar : PubMed/NCBI
6	Yi CH, Smith DJ, West WW and Hollingsworth MA: Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol. 170:1535–1545. 2007. View Article : Google Scholar : PubMed/NCBI
7	Albig AR and Schiemann WP: Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol. 23:367–379. 2004. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y and Marmorstein LY: Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res. 90:374–375. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sadr-Nabavi A, Ramser J, Volkmann J, et al: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer. 124:1727–1735. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yue W, Dacic S, Sun Q, et al: Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res. 13:4336–4344. 2007. View Article : Google Scholar : PubMed/NCBI
11	Nomoto S, Kanda M, Okamura Y, et al: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lecka-Czernik B, Lumpkin CK Jr and Goldstein S: An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol Cell Biol. 15:120–128. 1995.PubMed/NCBI
13	Hata K, Dhar DK, Watanabe Y, et al: Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer. Eur J Cancer. 43:1452–1459. 2007. View Article : Google Scholar : PubMed/NCBI
14	Albig AR, Neil JR and Schiemann WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI
15	Hu B, Thirtamara-Rajamani KK, Sim H and Viapiano MS: Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res. 7:1756–1770. 2009. View Article : Google Scholar : PubMed/NCBI
16	Seeliger H, Camaj P, Ischenko I, et al: EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res. 7:189–198. 2009. View Article : Google Scholar : PubMed/NCBI
17	Wang R, Zhang YW and Chen LB: Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer. 69:239–244. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kim EJ, Lee SY, Woo MK, et al: Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol. 40:402–408. 2012.PubMed/NCBI
19	Tong JD, Jiao NL, Wang YX, Zhang YW and Han F: Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma. 58:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
20	Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430. 2005. View Article : Google Scholar : PubMed/NCBI
21	Osta WA, Chen Y, Mikhitarian K, et al: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004. View Article : Google Scholar : PubMed/NCBI
22	Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
23	Pass HI, Levin SM, Harbut MR, et al: Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 367:1417–1427. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hsu HH, Liu CJ, Shen CY, et al: p38α MAPK mediates 17β-estradiol inhibition of MMP-2 and −9 expression and cell migration in human lovo colon cancer cells. J Cell Physiol. 227:3648–3660. 2012.
25	Kumar B, Koul S, Petersen J, et al: p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer Res. 70:832–841. 2010. View Article : Google Scholar : PubMed/NCBI